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Case report: Dystonia in a Fragile X Carrier
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Introduction
The Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder
that can affect both male and female carriers of a premutation expansion (55-200 CGG
repeats) of the fragile X mental retardation 1 (FMR1) gene. It is presumed to be caused by
elevated FMR1-mRNA leading to toxicity. Clinical features of FXTAS include progressive
cerebellar ataxia and intention tremor [1]. Associated symptoms are peripheral neuropathy,
cognitive impairment and dementia [2]. MRI findings of brain atrophy and white matter
disease are present in almost all cases but involvement of the middle cerebellar peduncles
occurs in 59% of males and 13% of females affected by FXTAS [3].
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Oromandibular dystonia (OMD), on the other hand, is a variant of focal dystonia that affects
women more often then men with the age of onset between 31-58 years [4]. In this report,
we present a patient with the premutation, symptoms of early FXTAS and severe OMD.
Case Report
About four years after beginning a new job that included conducting phone surveys a 48-
year-old female with 150 CGG repeats in her FMR1 gene noticed slurred speech and
uncontrollable tongue and jaw movements (Video). In the past year she developed a mild
tremor in her arms but it was not persistent. She has a history of poor balance throughout her
life that became worse over the two years prior to her initial study visit. She was
subsequently diagnosed with FXTAS. She also has a history of headaches, restless leg
syndrome, osteoarthritis, type II diabetes, sensory neuropathy, and borderline hypertension.
Over the last year she has a history of weakness and chronic fatigue in addition to
irritability.
On clinical examination the patient exhibited hyperkinetic dystonic spontaneous movements
of tongue and jaw (Video). Her tongue was large, protruding, and weak. Her exam, based on
FXTAS rating scale [5], revealed a slight terminal tremor during finger-to-nose touching
with no postural or resting tremor. She was mildly ataxic on heel to shin movements
(Video). However her gait was normal. Deep tendon reflexes were decreased in the upper
extremities and in ankles bilaterally, but were normal at the knees. Muscle strength was
normal in all 4 extremities. Vibration sensation was decreased in the big toes bilaterally.
Plantar reflexes were flexor bilaterally. Snout reflex positive for 1-3 taps, jaw jerk reflex
was present. Her neuropsychological examination results are represented in table 1.
On her previous MRI there is some mild cerebellar atrophy noted. Our MRI demonstrated
prominent perivascular spaces and mild dilation of the ventricles but no significant white
matter disease.
The patient was treated with carbidopa/levodopa 25/100 with a gradual increasing dose up to
2 ½ pills three time a day. Her symptoms improved but the occasional vocal slurring and
mild problems with chewing were still present.
Discussion
This case represents the first diagnosis of OMD in a patient with the premutation who has
possible mild symptoms of FXTAS, however she does not have radiological features of
FXTAS; nor does she have the pattern of cognitive/executive impairments typically
associated with FXTAS as her MMSE, WMS-III, COWAT and CVLT were normal (Table
1).
Her clinical course were thought to be classic of OMD with typical tongue movements and
suppression of her hyperkinesis by a self-discovered sensory trick (suppression of the
involuntary movements with chewing on a pencil). We were somewhat surprised to see her
dramatic improvement on Levodopa since Levodopa has not been consistently shown
effective in treating focal dystonia and, in contrast, has been implicated in causing certain
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forms of facial dystonia [6]. An alternative treatment for OMD would be botulinum
injections [4].
This is the first case of OMD in a carrier female. It is not certain whether her OMD is a
clinical expression of her premutation or represents an independent disorder. It is speculated
however that the findings of inclusions in the hypoglossal nuclei in some autopsy FXTAS
cases [7] may suggest a common pathology contributing to the tongue hyperkinesis as
observed in this case.
It is possible that the OMD is part of a neurological spectrum seen in premutation carriers
that is related to RNA toxicity, particularly in the thalamus. More cases of OMD would have
to be seen to know if there is a relationship with FXTAS or the premutation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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MMSE 30 of 30
WAIS-III IQ verbal 94
IQ performance 84
IQ full scale 89
WMS-III General Memory Score 89
Purdue Pegboard 25th percentile
COWAT / CVLT No impairment
SCL-90-R Somatization T 60
Interpersonal Sensitivity T 66
Depression T 64
Psychoticism T 60
Global Severity Index T 61
SCID Social Phobia (300.23)
Adjustment disorder with depressed mood (309.0)
T = normative score with an average range of 40-59
MMSE = Mini-Mental State Examination (Folstein [10]1975), WAIS = Wechsler Adult Intelligence Scale [11], COWAT = Controlled Oral Word
Association Test [12], CVLT = California Verbal Learning Test (Delis, Kramer, Kaplan, & Ober 1987, 2000), WMS-III = Wechsler Memory
Scale-Third Edition [13], SCL-90-R = Symptom Checklist 90-Revised [14], SCID = Structured Clinical Interview for DSM-IV Axis I [15 2002]
Mov Disord. Author manuscript; available in PMC 2015 June 01.
